Propel Bio Partners Research
Investment Thesis
Propel Bio Partners is a Los Angeles-founded and headquartered venture/incubator hybrid firm, founded in 2022 by Dr. Leen Kawas (former CEO of Athira Pharma, now LeonaBio) and Richard Kayne (founder of Kayne Anderson Capital Advisors). The firm backs companies developing therapies for rare diseases and other high-need conditions with significant unmet needs, concentrating on late-stage assets approaching key clinical and regulatory milestones or already in active development. Propel's core conviction, as articulated by managing general partner Dr. Kawas, is that in medicine, scientific breakthroughs are no longer enough. Too many promising therapies fail not because the science is flawed but because execution, regulatory navigation, commercialization strategy, and operational discipline fall short. Propel's hybrid model pairs capital with hands-on operational support across clinical strategy, regulatory planning, and commercialization, aiming to reduce execution risk for portfolio companies.
Sector Focus
Propel focuses on:
- Rare disease therapeutics
- Late-stage biotech assets nearing regulatory milestones
- Infectious disease and hepatology (e.g., chronic hepatitis D)
- Diagnostics and point-of-care pathogen detection
- Reproductive health and microbiome science
Stage Focus
Propel's investments span Seed through Series A and into public/post-IPO positions in late-stage biotech companies, reflecting the firm's emphasis on later-stage, de-risked assets nearing regulatory milestones alongside occasional earlier-stage bets tied to its incubator/hands-on model (e.g., Persephone Biosciences seed, Inherent Biosciences Series A, EIT Pharma Series A).
Check Size
No specific check-size range is publicly disclosed. Propel co-led Persephone Biosciences' $15M seed round (2022), led Inherent Biosciences' Series A (2022), and led EIT Pharma's oversubscribed $35M Series A (August 2026). It also holds a post-IPO equity position in Achieve Life Sciences (NASDAQ: ACHV), a specialty pharmaceutical company advancing cytisinicline for nicotine dependence.
Lead Tendency
Propel has both led and co-led rounds: it led Inherent Biosciences' Series A financing, led EIT Pharma's $35M Series A, and co-led Persephone Biosciences' $15M seed round alongside First Bight Ventures and others.
Recent Activity
The firm closed a new $100M fund (announced May 2026), continuing to target late-stage biotech assets across infectious disease, oncology, and other high-need therapeutic areas, with an emphasis on near-term development milestones. In August 2026, portfolio company EIT Pharma received FDA acceptance of a New Drug Application for lonafarnib to treat chronic hepatitis D, and shortly after closed an oversubscribed $35M Series A led by Propel to fund continued FDA review activities and manufacturing/commercial readiness. Portfolio company Achieve Life Sciences previously received a Complete Response Letter from the FDA for its cytisinicline NDA (2026), following FDA acceptance of that NDA filing in late 2025.
Portfolio Highlights
- Achieve Life Sciences (NASDAQ: ACHV) - late-stage specialty pharmaceutical company developing cytisinicline for smoking/nicotine cessation; Propel holds a post-IPO equity position.
- EIT Pharma - Kirkland, WA-based biotech developing lonafarnib for chronic hepatitis D (NDA under FDA review); closed an oversubscribed $35M Series A led by Propel in August 2026; frequently cited by Propel as the clearest expression of its hybrid capital-plus-operational-support model.
- Persephone Biosciences - San Diego-based synthetic biology company developing microbiome-based (synbiotic) therapeutics for infant and patient gut health; Propel co-led its $15M seed round; prior collaborations with Ginkgo Bioworks and Janssen.
- Inherent Biosciences - Salt Lake City-based epigenetic diagnostics and therapeutics company (lead product SpermQT for male-fertility testing); Propel led its Series A; the company later partnered with Posterity Health.
- OmniVis - developer of a handheld, smartphone-enabled device for rapid cholera pathogen detection in water/field settings, using loop-mediated isothermal amplification and particle diffusometry.
Team
- Leen Kawas, PhD - Managing General Partner and co-founder. Former CEO of Athira Pharma (now LeonaBio), which she took public in 2020 (raised over $400M); serves on the boards of Inherent Biosciences and Persephone Biosciences.
- Richard Kayne, MBA - General Partner. Founder and co-chairman of Kayne Anderson Capital Advisors; founder of Kayne Anderson Rudnick.
- Xue Hua, PhD - Managing Partner, based in Seattle; clinical research, clinical operations, and data science background.
- Jim Harding, CPA, CMA - Finance.
- Erik Gonzalez-Leon, PhD - Manager, biomedical engineering translational research and technical/patentability assessment.
- Joyce Jiang, MPH, PhD - Vice President, health economics, market access, business development, and clinical trial design.
- Safiya Alavi - Analyst.
- Armaan Hirani - Data Science Associate.
- Laurie Heilmann - Venture Partner, commercialization and accelerator strategy.
Decision Process
Propel operates as a partnership between managing general partner Dr. Leen Kawas and general partner Richard Kayne, supported by an internal investment team (Xue Hua, Erik Gonzalez-Leon, Joyce Jiang, and analysts) and a broad medical/investment advisory board that provides clinical, regulatory, and commercial diligence input.
Founder Preferences
Propel favors founders and management teams with credible late-stage clinical or regulatory paths, particularly in rare diseases and areas of significant unmet medical need. The firm places heavy weight on execution capability - clinical, regulatory, and commercial rigor - over pure scientific novelty, and looks for teams open to hands-on operational partnership rather than passive capital.
Geographic Focus
Propel is headquartered in Los Angeles, CA, with a portfolio concentrated in the United States (Seattle, San Diego, Salt Lake City, Kirkland WA, and West Lafayette, IN).